HAISCO PHARMACEUTICAL GROUP CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 27.28 CNY | +1.41% |
|
+3.18% | +17.84% |
| Apr. 19 | Haisco Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Apr. 18 | Haisco Pharmaceutical Gets Nod to Trial HSK16149 Capsules | MT |
| Sales 2024 * | 3.88B 535M | Sales 2025 * | 5.1B 704M | Capitalization | 30.1B 4.15B |
|---|---|---|---|---|---|
| Net income 2024 * | 552M 76.19M | Net income 2025 * | 633M 87.37M | EV / Sales 2024 * | 7.77 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 5.9 x |
| P/E ratio 2024 * |
53.8
x | P/E ratio 2025 * |
47.6
x | Employees | 5,448 |
| Yield 2024 * |
0.45% | Yield 2025 * |
0.56% | Free-Float | 20.41% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +1.89% | ||
| 1 week | +1.74% | ||
| Current month | -0.85% | ||
| 1 month | +2.16% | ||
| 3 months | +19.82% | ||
| 6 months | +18.19% | ||
| Current year | +16.20% |
1 week
25.13
27.30
1 month
25.1327.59
Current year
18.5928.43
1 year
18.5928.43
3 years
12.9329.29
5 years
11.0830.00
10 years
9.4339.50
| Managers | Title | Age | Since |
|---|---|---|---|
Xiu Lian Fan
CEO | Chief Executive Officer | 61 | 06-12-31 |
Peng Duan
DFI | Director of Finance/CFO | 49 | 16-10-20 |
Jun Min Wang
CHM | Chairman | 56 | 06-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jun Min Wang
CHM | Chairman | 56 | 06-12-31 |
Wei Zheng
BRD | Director/Board Member | 54 | 06-12-31 |
Xiu Lian Fan
CEO | Chief Executive Officer | 61 | 06-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-23 | 27.28 | +1.41% | 3 321 500 |
| 24-04-23 | 26.9 | +1.89% | 4,695,500 |
| 24-04-22 | 26.4 | +1.89% | 5,111,822 |
| 24-04-19 | 25.91 | +2.01% | 5,618,800 |
| 24-04-18 | 25.4 | -6.58% | 6,917,400 |
End-of-day quote Shenzhen S.E., April 22, 2024
More quotes
Haisco Pharmaceutical Group Co.,Ltd., formerly Xizang Haisco Pharmaceutical Group Co., Ltd., is a China-based company principally engaged in the research, development, manufacture and sale of new drugs and high-end medical instrument. The Companyâs main products are categorized into small volume injections, big volume injections, freeze-dried powder injections and others, which include polyene phosphatidylcholine injections, lipid solubility vitamins injection series, doradiazine methanesulfonate injections, nalmefene hydrochloride injections, fluprofen tromethamine tablets and cefoperazone sodium tazobactam sodium for injections, among others. The Company distributes its products in domestic market.
Sector
Pharmaceuticals
Calendar
2024-05-15
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
26.9
Average target price
-
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +16.20% | 4.1B | |
| +27.21% | 672B | |
| +26.73% | 570B | |
| -5.87% | 360B | |
| +15.34% | 321B | |
| +8.00% | 300B | |
| +7.51% | 217B | |
| -9.24% | 204B | |
| +5.66% | 199B | |
| -8.60% | 149B |
- Stock Market
- Equities
- 002653 Stock
